Episode Details
Back to Episodes
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Episode 1168
Published 1 year, 11 months ago
Description
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib